FRAMINGHAM, Mass. and SYDNEY, Dec. 2, 2010 /PRNewswire/ —
HeartWare International, Inc. (Nasdaq:
HTWR) (ASX: HIN), a leading innovator of less invasive,
miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is scheduled to make an investor
presentation at the Canaccord Genuity Cardio/Diabetes & Obesity
Conference on Tuesday, December 7, 2010 at 9:00 a.m. Pacific Time
(noon, Eastern Time). The conference is being held December
7-8, 2010 at the Nikko Hotel in San Francisco.
A live webcast of the Company’s presentation at the conference
will be available via a link provided at www.heartware.com. An
archived replay of the presentation will also be available shortly
after the presentation time for a period of 15 days.
About HeartWare InternationalHeartWare International develops
and manufactures miniaturized implantable heart pumps, or
ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare®
Ventricular Assist System features the HVAD® pump, a small
full-output circulatory support device (up to 10L/min flow)
designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices.
HeartWare has received CE Marking for the HeartWare System in
the European Union. The device is currently the subject of
United States clinical trials for two indications:
bridge-to-transplant under a continued access protocol and
destination therapy. For additional information, please visit
www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The NASDAQ
Stock Market and the Aust
‘/>”/>
